Abstract:New, safe and effective drugs are urgently needed to treat and control malaria and tuberculosis, which affect millions of people annually. However, financial return on investment in the poor settings where these diseases are mostly prevalent is very minimal to support market-driven drug discovery and development. Moreover, the imminent loss of therapeutic lifespan of existing therapies due to evolution and spread of drug resistance further compounds the urgency to identify novel effective drugs. However, the advent of new public-private partnerships focused on tropical diseases and the recent release of large data sets by pharmaceutical companies on antimalarial and antituberculosis compounds derived from phenotypic whole cell high throughput screening have spurred renewed interest and opened new frontiers in malaria and tuberculosis drug discovery. This Account recaps the existing challenges facing antimalarial and antituberculosis drug discovery, including limitations associated with experimental animal models as well as biological complexities intrinsic to the causative pathogens. We enlist various highlights from a body of work within our research group aimed at identifying and characterizing new chemical leads, and navigating these challenges to contribute toward the global drug discovery and development pipeline in malaria and tuberculosis. We describe a catalogue of in-house efforts toward deriving safe and efficacious preclinical drug development candidates via cell-based medicinal chemistry optimization of phenotypic whole-cell medium and high throughput screening hits sourced from various small molecule chemical libraries. We also provide an appraisal of target-based screening, as invoked in our laboratory for mechanistic evaluation of the hits generated, with particular focus on the enzymes within the de novo pyrimidine biosynthetic and hemoglobin degradation pathways, the latter constituting a heme detoxification process and an associated cysteine protease-mediated hydrolysis of hemoglobin. We further expound on the recombinant enzyme assays, heme fractionation experiments, and genomic and chemoproteomic methods that we employed to identify Plasmodium falciparum falcipain 2 (PfFP2), hemozoin formation, phosphatidylinositol 4-kinase (PfPI4K) and Mycobacterium tuberculosis cytochrome bc1 complex as the targets of the antimalarial chalcones, pyrido[1,2-a]benzimidazoles, aminopyridines, and antimycobacterial pyrrolo[3,4-c]pyridine-1,3(2H)-diones, respectively. In conclusion, we argue for the expansion of chemical space through exploitation of privileged natural product scaffolds and diversity-oriented synthesis, as well as the broadening of druggable spaces by exploiting available protein crystal structures, -omics data, and bioinformatics infrastructure to explore hitherto untargeted spaces like lipid metabolism and protein kinases in P. falciparum. Finally, we audit the merits of both target-based and whole-cell phenotypic screening in steering antimalarial and antituberculosis chemical matter toward populating drug discovery pipelines with new lead molecules.

Cover Feature: Chemoproteomics for Plasmodium Parasite Drug Target Discovery (ChemBioChem 16/2021)

Chemoproteomics: Towards Global Drug Target Profiling

A novel chemogenomic screening platform for scalable antimalarial drug target identification

Proteomic Profiling of Antimalarial Plasmodione Using 3‐Benz(o)ylmenadione Affinity‐Based Probes

A proteomic view of the Plasmodium falciparum life cycle

Exploiting integrative metabolomics to study host–parasite interactions in Plasmodium infections

Computational approach for decoding malaria drug targets from single-cell transcriptomics and finding potential drug molecule

Insights into Integrated Lead Generation and Target Identification in Malaria and Tuberculosis Drug Discovery

Unveiling Potential Repurposed Drug Candidates for Plasmodium falciparum through In Silico Evaluation: A Synergy of Structure-based Approaches, Structure Prediction, and Molecular Dynamics Simulations

Bioactive compounds as therapeutic proposals against Plasmodium falciparum : A systematic review

Prioritization of Molecular Targets for Antimalarial Drug Discovery

Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum

Plasmodial Hsp40s: New Avenues for Antimalarial Drug Discovery

Functional Proteome and Expression Analysis of Sporozoites and Hepatic Stages of Malaria Development

Novel Highlight in Malarial Drug Discovery: Aspartate Transcarbamoylase

Host cell CRISPR genomics and modelling reveal shared metabolic vulnerabilities in the intracellular development of Plasmodium falciparum and related hemoparasites

Discovery of dual-target natural antimalarial agents against DHODH and PMT of Plasmodium falciparum: pharmacophore modelling, molecular docking, quantum mechanics, and molecular dynamics simulations

Chemogenomic Profiling of a Plasmodium falciparum Transposon Mutant Library Reveals Shared Effects of Dihydroartemisinin and Bortezomib on Lipid Metabolism and Exported Proteins

DeepMalaria: Artificial Intelligence Driven Discovery of Potent Antiplasmodials

Deep Learning-driven research for drug discovery: Tackling Malaria

Exploring the recent pioneering developments of small molecules in antimalarial drug armamentarium: A chemistry prospective appraisal